Biologics for Severe Asthma: A Growing Treatment Class
This CME-accredited four-part CME Snapshot™ series is intended for pulmonologists, allergists, and other specialists involved in the long-term care of patients with severe asthma. In this educational series, expert faculty will review clinical practice guidelines, discuss new approaches to therapy, and hear directly from patients with severe asthma.
This activity has been designed to meet the educational needs of pulmonologists, allergists, and other specialists responsible for the long-term care of patients with severe asthma.
Upon completion of this activity, participants will be better able to do the following:
- Describe the mechanisms of action, published evidence, and prescribing considerations for biologic therapies in severe asthma
Monica Kraft, MD
Reynold A. Panettieri, Jr, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
|Monica Kraft, MD|
Grant/Research:Chiesi USA, Inc.; F. Hoffman-La Roche Ltd.; National Institutes of Health; sanofi-aventis U.S. LLC
Consultant/Advisor: AstraZeneca; Teva Pharmaceutical Industries Ltd.
|Reynold A. Panettieri, Jr, MD|
Speakers’ Bureau: AstraZeneca; Boehringer-Ingelheim; Boston Scientific Corporation; MedImmune, LLC; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.
Consultant/Advisor: AstraZeneca; MedImmune, LLC; Novartis Pharmaceuticals CorporationResearch Grant: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; Gilead Sciences, Inc.; MedImmune, LLC; Novartis Pharmaceuticals Corporation; OncoArendi Therapeutics SA; RFIM; sanofi-aventis U.S. LLC; Theratrophix, LLC; Vertex Pharmaceuticals Incorporated
Non-faculty: Rose O’Connor, PhD, CHCP; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from AstraZeneca.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, and AstraZeneca do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Non-physician